Background: This retrospective study was performed to develop a model to predict the maintenance dosage of the vitamin K antagonist acenocoumarol, based upon the first INR after a standard initial dosage regimen.
Material And Methods: Outpatients with atrial fibrillation ( n = 284) and initial regimens of 6-4 or 6-4-2 mg acenocoumarol on day 1, 2 and 3, respectively, were included. The maintenance dosage of the period 3-6 months after the installment was related to the first INR after those standard initial dosage regimens, because in that period the INR was 76% of the time within the therapeutic range and therefore considered suitable to perform the analysis.
Results: A clear relation was found between the first INR, the maintenance dosage and the age. A model that predicts the maintenance dosage immediately after the standard initial dosage and based on the first INR and adjusted for age, has been developed, according to the formula: required dosage = 5.03-1.65 * ln (first INR) - 0.01 * age.
Conclusion: We have developed a formula to predict the maintenance dosage of acenocoumarol. With this formula it is possible to install this maintenance dosage and thus achieve oral anticoagulant therapy within the therapeutic range at an earlier stage. This will have to be shown in a prospective study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/B:THRO.0000011375.12034.62 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Delay discounting predicts COVID-19 vaccine booster willingness.
Cogn Res Princ Implic
January 2025
Department of Psychology and Centre for Integrative and Applied Neuroscience, York University, 4700 Keele St., Toronto, ON, M3J 1P3, Canada.
Developing ways to predict and encourage vaccine booster uptake are necessary for durable immunity responses. In a multi-nation sample, recruited in June-August 2021, we assessed delay discounting (one's tendency to choose smaller immediate rewards over larger future rewards), COVID-19 vaccination status, demographics, and distress level. Participants who reported being vaccinated were invited back one year later (n = 2547) to report their willingness to receive a booster dose, along with reasons for their decision.
View Article and Find Full Text PDFPembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction.
Oncologist
January 2025
HonorHealth Research Institute, Scottsdale, AZ, United States.
Lessons Learned: Intravenous paricalcitol did not improve the efficacy of pembrolizumab, likely related to the short half-life.
Background: Immunotherapy has limited benefit in the treatment of advanced pancreatic cancer with the tumor microenvironment playing a key role in immune resistance. In preclinical studies, vitamin D receptor (VDR) agonists have been shown to sensitize pancreatic tumors to PD-1 blockade.
Effect of propofol and ciprofol in patients undergoing bronchoscopy: protocol for a double-blind, randomised controlled trial.
BMJ Open
January 2025
Department of Anesthesiology and Perioperative medicine, Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Clinical Research Center for Anesthesiology and Perioperative Medicine, Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China
Introduction: Propofol is a fast-acting intravenous anaesthetic widely used for sedation and anaesthesia in gastrointestinal endoscopy, bronchoscopy, and the induction/maintenance of general anaesthesia in outpatients and inpatients; however, propofol has several undesirable effects, including injection pain, which affects the physical and mental health of patients, and cardiopulmonary depression, characterised by hypotension, bradycardia and apnea, which commonly occur in clinical practice. Ciprofol (HSK3486) is a propofol analogue with good clinical safety, high potency and some advantages over propofol, including lower injection pain and haemodynamic depression in patients undergoing gastroscopy and colonoscopy. This study aims to compare the impact of equivalent effective doses of propofol and ciprofol on haemodynamic changes in patients undergoing bronchoscopy under general anaesthesia.
View Article and Find Full Text PDFMelatonin: A Review of the Evidence for Use in Hospital Settings.
Pharmacol Res Perspect
February 2025
Medication Safety (Formulary) Clinical Excellence Commission, Sydney, New South Wales, Australia.
New onset insomnia is often experienced by patients during hospitalization due to environmental disruptions, pain and increased patient care activities. Patient distress arising from poor sleep quality and quantity often results in the prescribing of hypnotics. Melatonin use in hospital settings is common and is increasingly used for off label indications including primary insomnia in those aged < 55 years, prevention of delirium and to facilitate benzodiazepine discontinuation.
View Article and Find Full Text PDFCase report: Watch-and-wait strategy in resectable esophageal cancer following neoadjuvant chemoimmunotherapy: a case series.
Front Immunol
January 2025
Department of Thoracic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Neoadjuvant chemoimmunotherapy (NCIT) has improved pathological complete response and conferred survival benefits in patients with locally advanced esophageal cancer. However, surgical complications unrelated to the tumor continue to detract from patient outcomes. While the "watch-and-wait" strategy has been implemented in clinical complete responders following neoadjuvant therapy for rectal cancer, there is a lack of evidence supporting its practicability in esophageal cancer after NCIT.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!